KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Change in Receivables (2020 - 2021)

Recursion Pharmaceuticals' Change in Receivables history spans 2 years, with the latest figure at -$16000.0 for Q3 2021.

  • For Q3 2021, Change in Receivables fell 100.05% year-over-year to -$16000.0; the TTM value through Dec 2021 reached -$114000.0, down 2380.0%, while the annual FY2021 figure was -$114000.0, 2380.0% down from the prior year.
  • Change in Receivables reached -$16000.0 in Q3 2021 per RXRX's latest filing, down from -$13000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $30.2 million in Q3 2020 to a low of -$30.0 million in Q4 2020.